Humanigen Announces Revised Time for Presentation at Jefferies London Healthcare Conference
November 16 2021 - 7:47AM
Business Wire
Humanigen, Inc. (Nasdaq: HGEN) (“Humanigen”), a clinical-stage
biopharmaceutical company focused on preventing and treating an
immune hyper-response called ‘cytokine storm,’ announced that its
presentation time at the Jefferies London Healthcare Conference has
been changed.
Jefferies London Healthcare Conference
Timothy Morris, COO and CFO, will now make a corporate
presentation at 9:20am EST on November 17, 2021. A livestream will
be accessible via the link below and a webcast link to a recording
of the event will be posted to the “Events and Presentations”
section of Humanigen’s investor relations website after the
event.
Webcast: https://wsw.com/webcast/jeff201/hgen/1823004 The
webcast will be available for 90 days under the Investor Relations
section of the company’s website at www.ir.humanigen.com
About Humanigen, Inc.
Humanigen, Inc. (Nasdaq: HGEN) (Humanigen), is a clinical-stage
biopharmaceutical company focused on preventing and treating an
immune hyper-response called ‛cytokine storm’. Lenzilumab is a
first-in class antibody that binds to and neutralizes
granulocyte-macrophage colony-stimulating factor (GM-CSF). Results
from preclinical models indicate GM-CSF is an upstream regulator of
many inflammatory cytokines and chemokines involved in the cytokine
storm. Early in the COVID-19 pandemic, investigation showed high
levels of GM-CSF secreting T cells were associated with disease
severity and intensive care unit admission. Humanigen’s Phase 3
LIVE-AIR study suggests early intervention with lenzilumab may
prevent cytokine storm in hospitalized patients with COVID-19.
Humanigen has submitted lenzilumab to Medicines and Health
Regulatory Agency in the United Kingdom for a rolling review
towards potential Conditional Marketing Authorization. Humanigen is
developing lenzilumab as a treatment for cytokine storm associated
with COVID-19 and CD19-targeted CAR-T cell therapies and is also
exploring the effectiveness of lenzilumab in other inflammatory
conditions such as acute Graft versus Host Disease in patients
undergoing allogeneic hematopoietic stem cell transplantation,
eosinophilic asthma, and rheumatoid arthritis. For more
information, visit www.humanigen.com and follow Humanigen on
LinkedIn, Twitter, and Facebook.
Forward-Looking Statements
All statements other than statements of historical facts
contained in this press release are forward-looking statements.
Forward-looking statements reflect management's current knowledge,
assumptions, judgment, and expectations regarding future
performance or events. Although management believes that the
expectations reflected in such statements are reasonable, they give
no assurance that such expectations will prove to be correct, and
you should be aware that actual events or results may differ
materially from those contained in the forward-looking statements.
Words such as "will," "expect," "intend," "plan," "potential,"
"possible," "goals," "accelerate," "continue," and similar
expressions identify forward-looking statements, including, without
limitation, statements regarding: Humanigen’s beliefs as to the
potential benefits of lenzilumab as a treatment for hospitalized
COVID-19 patients; its efforts to request and receive Conditional
Marketing Authorization for lenzilumab in COVID-19 in the UK and
other territories; its beliefs and projections regarding the need
for lenzilumab as a therapeutic if authorized or approved; and its
other plans to initiate or participate in planned clinical trials
and otherwise explore the effectiveness of lenzilumab and other
candidates in its development portfolio as therapies for other
inflammation and immune-oncology indications.
Forward-looking statements are subject to a number of risks and
uncertainties including, but not limited to, the risks inherent in
the company’s lack of profitability and need for additional capital
to conduct its business; its dependence on partners to further the
development of its product candidates; the uncertainties inherent
in the development, attainment of the requisite regulatory
authorizations and approvals and launch of any new pharmaceutical
product; challenges associated with manufacturing and
commercializing a biologic such as lenzilumab; the outcome of
pending or future litigation; and the various risks and
uncertainties described in the "Risk Factors" sections and
elsewhere in Humanigen's periodic and other filings with the
Securities and Exchange Commission.
All forward-looking statements are expressly qualified in their
entirety by this cautionary notice. You should not rely upon any
forward-looking statements as predictions of future events. The
Company undertakes no obligation to revise or update any
forward-looking statements made in this press release to reflect
events or circumstances after the date hereof or to reflect new
information or the occurrence of unanticipated events, except as
required by law.
View source
version on businesswire.com: https://www.businesswire.com/news/home/20211116005802/en/
Humanigen Investor Relations Ken Trbovich Humanigen
trbo@humanigen.com 650-410-3206
Humanigen (NASDAQ:HGEN)
Historical Stock Chart
From May 2024 to Jun 2024
Humanigen (NASDAQ:HGEN)
Historical Stock Chart
From Jun 2023 to Jun 2024